Hoechst Pakistan Limited engages in the manufacture, trading, and sale of pharmaceutical and related products in Pakistan, Afghanistan, and internationally. The company provides its allergy management, anti-diarrheals, antiemetic, antibiotic, cardiology, consumer healthcare, diabetes, and emergency care products under Flagyl, Clexane, Lantus, Amaryl, Claforan, Haemaccel, Secnidazole forte, Rulid, Targocid, Tavanic, Tarivid, Aventriax, Stemetil, Lasix, Winstor, Tritace, Cordarone, CoAprovel, Aprovel, CoPlavix, Selsun Blue, Apidra, Toujeo, Soliqua, Daonil, Neodipar, Enterogermina, and Plavix brands. The company was formerly known as Sanofi-Aventis Pakistan Limited and changed its name to Hoechst Pakistan Limited in September 2023. Hoechst Pakistan Limited was incorporated in 1967 and is headquartered in Karachi, Pakistan.
Q4 2025 is off to a flying start with record highs being printed left, right, and center. US and Japanese stocks made fresh new highs, while the gold price powered through $4,000 for the first time, and Bitcoin crossed the $126k level. Is this all a case of USD weakness, irrational exuberance, or solid fundamentals? This week, we are reviewing Q3 market performance, Q2 earnings season, and the outlook heading into the end of 2025…
Over the last 7 days, the market has dropped 2.4%, driven by losses in the Financials and Energy sectors of 3.1% and 3.8%, respectively. In contrast, the Communication Services sector has actually gained 15%. In contrast to the last week, the market is actually up 69% over the past year. As for the next few years, earnings are expected to grow by 11% per annum. Market details ›